Document:

Exhibit 10.1

 

DIGITAL TURBINE, INC.

 

A Delaware
corporation

  

 

 

8.75% CONVERTIBLE NOTES DUE 2020

  

 

 

INITIAL
PURCHASER AGREEMENT

 

September 23, 2016

 

     

     

    

 

 

CONVERTIBLE NOTE INITIAL
PURCHASER AGREEMENT

 

Digital Turbine, Inc., a Delaware corporation
(the “Company”), proposes to issue and sell to BTIG, LLC (the “Initial Purchaser”)
$16,000,000 principal amount of its 8.75% convertible notes due September 23, 2020 (the “Notes”). The Notes
will be unconditionally guaranteed as to the payment of principal, premium, if any, and interest on a senior unsecured basis (the
“Guarantee” and together with the Notes, the “Securities”) by the wholly-owned subsidiaries
of the Company listed on the signature pages hereto as guarantors (the “Guarantors”). The Securities will be
issued pursuant to the provisions of an Indenture, which will be substantially in the form attached hereto as Exhibit A (the “Indenture”),
to be entered into on the Closing Date (as defined below), among the Company, the Guarantors and U.S. Bank National Association,
as trustee (the “Trustee”). The Notes will be convertible into shares of common stock of the Company (the “Underlying
Securities”). On the Closing Date, the Company and U.S. Bank National Association, as warrant agent (the “Warrant
Agent”) will also enter into a warrant agreement, which will be substantially in the form attached hereto as Exhibit
B (the “Warrant Agreement”).

 

The Securities will be offered to the Initial
Purchaser without being registered under the Securities Act of 1933, as amended (the “Securities Act”), in reliance
on the exemption from the registration requirements of the Securities Act provided by Section 4(a)(2) thereof. The Initial Purchaser
has advised the Company that it will make offers and resales of the Securities purchased from the Company to qualified institutional
buyers in compliance with the exemption from registration provided by Rule 144A under the Securities Act and to institutional accredited
investors (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act).

 

The Initial Purchaser and its direct and
indirect transferees will be entitled to the benefits of a Registration Rights Agreement, which will be substantially in the form
attached hereto as Exhibit C (the “Registration Rights Agreement”), to be entered into on the Closing Date,
among the Company, the Guarantors and the Initial Purchaser.

 

In connection with the sale of the Securities,
the Company and the Guarantors have prepared a preliminary offering memorandum dated September 22, 2016 (the “Preliminary
Memorandum”) and will prepare a final offering memorandum (the “Final Memorandum”) including or incorporating
by reference a description of the terms of the Securities and the Underlying Securities, the terms of the offering and a description
of the Company and the Guarantors. For purposes of this Agreement, “Additional Written Offering Communication”
means any written communication (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or a solicitation
of an offer to buy the Securities other than the Preliminary Memorandum or the Final Memorandum, and “Time of Sale Memorandum”
means the Preliminary Memorandum together with the Additional Written Offering Communications, if any, each identified in Schedule
I hereto. As used herein, the terms Preliminary Memorandum, Time of Sale Memorandum and Final Memorandum shall include the
documents, if any, incorporated by reference therein on the date hereof. The terms “supplement”, “amendment”
and “amend” as used herein with respect to the Preliminary Memorandum, the Time of Sale Memorandum, the Final
Memorandum or any Additional Written Offering Communication shall include all documents subsequently filed by the Company or the
Guarantors with the Securities and Exchange Commission (the “Commission”) pursuant to the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), that are deemed to be incorporated by reference therein.

 

     

     

    

 

1.          Representations
and Warranties. The Company and the Guarantors, jointly and severally, represent and warrant to, and agree with, the Initial
Purchaser that:

 

(a)          (i)
Each document, if any, filed or to be filed pursuant to the Exchange Act and incorporated by reference in the Preliminary Memorandum,
the Time of Sale Memorandum or the Final Memorandum complied with, or will comply with, when filed in all material respects with
the Exchange Act and the applicable rules and regulations of the Commission thereunder, (ii) the Time of Sale Memorandum does not
at the time of each sale of the Securities in connection with the offering when the Final Memorandum is not yet available to prospective
purchasers and at the Closing Date (as defined in Section ‎4), the Time
of Sale Memorandum, as then amended or supplemented by the Company and the Guarantors, if applicable, will not, contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
under which they were made, not misleading, (iii) the Preliminary Memorandum does not contain and the Final Memorandum, in the
form used by the Initial Purchaser to confirm sales and on the Closing Date (as defined in Section 4), will not contain
any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading, except that the representations and warranties set forth in this
paragraph do not apply to statements or omissions in the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum
based upon information relating to the Initial Purchaser furnished to the Company in writing by such Initial Purchaser expressly
for use therein.

 

(b)          Except
for the Additional Written Offering Communications, if any, identified in Schedule I hereto, and electronic road shows,
if any, furnished to the Initial Purchaser before first use, the Company and the Guarantors have not prepared, used or referred
to, and will not, without the prior consent of the Initial Purchaser, prepare, use or refer to, any Additional Written Offering
Communication.

 

(c)          The
Company has been duly incorporated, is validly existing as a corporation in good standing under the laws of the State of Delaware,
has the corporate power and authority to own its property and to conduct its business as described in the Time of Sale Memorandum
and is duly qualified to transact business and is in good standing in each jurisdiction in which the conduct of its business or
its ownership or leasing of property requires such qualification, except to the extent that the failure to be so qualified or be
in good standing would not have a material adverse effect on the Company and its subsidiaries, taken as a whole.

 

    2 

     

    

 

(d)          Each
subsidiary of the Company has been duly incorporated, is validly existing as a corporation or a limited liability company, as applicable,
in good standing under the laws of the jurisdiction of its incorporation, has the corporate power and authority to own its property
and to conduct its business as described in the Time of Sale Memorandum and is duly qualified to transact business and is in good
standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property requires such qualification,
except to the extent that the failure to be so qualified or be in good standing would not have a material adverse effect on the
Company and its subsidiaries, taken as a whole; all of the issued shares of capital stock of each subsidiary of the Company have
been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly by the Company, and at the
Closing Date will be free and clear of all liens, encumbrances, equities or claims.

 

(e)          This
Agreement has been duly authorized, executed and delivered by the Company and the Guarantors.

 

(f)          The
authorized capital stock of the Company conforms as to legal matters to the description thereof contained in each of the Time of
Sale Memorandum and the Final Memorandum.

 

(g)          The
shares of common stock of the Company outstanding prior to the issuance of the Securities have been duly authorized and are validly
issued, fully paid and non-assessable.

 

(h)          The
common stock of the Company is registered pursuant to the Exchange Act and is listed on NASDAQ, and the Company has taken no action
designed to terminate the registration of its common stock under the Exchange Act or to delist its common stock from NASDAQ, nor
has the Company received any notification that the Commission or NASDAQ is contemplating terminating such registration or listing.

 

(i)          The
Securities have been duly authorized and, when executed and authenticated in accordance with the provisions of the Indenture and
the Warrant Agreement and delivered to and paid for by the Initial Purchaser in accordance with the terms of this Agreement, will
be valid and binding obligations of the Company or the Guarantors, as applicable, enforceable in accordance with their terms, subject
to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles of general
applicability, and will be entitled to the benefits of the Indenture, the Registration Rights Agreement and the Warrant Agreement
pursuant to which such Securities are to be issued. The Guarantee conforms to the description thereof in the Time of Sale Memorandum
and the Final Memorandum.

 

    3 

     

    

 

(j)          The
Underlying Securities issuable upon conversion of the Securities have been duly authorized and reserved and, when issued upon conversion
of the Securities in accordance with the terms of the Securities, will be validly issued, fully paid and non-assessable, and the
issuance of the Underlying Securities will not be subject to any preemptive or similar rights.

 

(k)          Each
of the Indenture, the Registration Rights Agreement and the Warrant Agreement has been duly authorized, and, as of the Closing
Date, will be duly executed and delivered by, and will be a valid and binding agreement of, the Company, enforceable in accordance
with its terms, subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable
principles of general applicability.

 

(l)          Each
of the Indenture and the Registration Rights Agreement has been duly authorized, and, as of the Closing Date, will be duly executed
and delivered by, and will be a valid and binding agreement of, each of the Guarantors, enforceable in accordance with its terms,
subject to applicable bankruptcy, insolvency and similar laws affecting creditors’ rights generally and equitable principles
of general applicability.

 

(m)          The
execution and delivery by the Company of, and the performance by the Company of its obligations under, this Agreement, the Indenture,
the Registration Rights Agreement, the Warrant Agreement and the Securities will not contravene any provision of applicable law
or the certificate of incorporation or by-laws of the Company or any agreement or other instrument binding upon the Company or
any of its subsidiaries that is material to the Company and its subsidiaries, taken as a whole, or any judgment, order or decree
of any governmental body, agency or court having jurisdiction over the Company or any subsidiary, and no consent, approval, authorization
or order of, or qualification with, any governmental body or agency is required for the performance by the Company of its obligations
under this Agreement, the Indenture, the Registration Rights Agreement, the Warrant Agreement or the Securities, except such as
may be required by the securities or Blue Sky laws of the various states in connection with the offer and sale of the Securities
and by federal and state securities laws with respect to the Company’s obligations under the Registration Rights Agreement.

 

(n)          The
execution and delivery by the Guarantors of, and the performance by the Guarantors of their respective obligations under, this
Agreement, the Indenture, the Registration Rights Agreement and the Securities will not contravene any provision of applicable
law or the certificates of incorporation or by-laws of the various Guarantors or any agreement or other instrument binding upon
the Guarantors or any of their subsidiaries that is material to a given Guarantor and its subsidiaries, taken as a whole, or any
judgment, order or decree of any governmental body, agency or court having jurisdiction over the Guarantors or any of their subsidiaries,
and no consent, approval, authorization or order of, or qualification with, any governmental body or agency is required for the
performance by the Guarantors of their respective obligations under this Agreement, the Indenture, the Registration Rights Agreement
or the Securities, except such as may be required by the securities or Blue Sky laws of the various states in connection with the
offer and sale of the Securities and by federal and state securities laws with respect to the Guarantors’ obligations under
the Registration Rights Agreement.

 

    4 

     

    

 

(o)          There
has not occurred any material adverse change, or development involving a reasonably likely prospective material adverse change,
in the condition, financial or otherwise, or in the earnings, business or operations of the Company and its subsidiaries, taken
as a whole, from that set forth in the Time of Sale Memorandum provided to prospective purchasers of the Securities.

 

(p)          Other
than proceedings accurately described in all material respects in the Time of Sale Memorandum, there are no legal or governmental
proceedings pending or threatened to which the Company or any of its subsidiaries is a party or to which any of the properties
of the Company or any of its subsidiaries is subject that would have a material adverse effect on the Company and its subsidiaries,
taken as a whole, or on the power or ability of the Company or the Guarantors to perform their respective obligations under this
Agreement, the Indenture, the Registration Rights Agreement, the Warrant Agreement or the Securities or to consummate the transactions
contemplated by the Time of Sale Memorandum.

 

(q)          The
Company and its subsidiaries (i) are in compliance with any and all applicable foreign, federal, state and local laws and regulations
relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants or
contaminants, (ii) have received all permits, licenses or other approvals required of them under applicable laws to conduct
their respective businesses and (iii) are in compliance with all terms and conditions of any such permit, license or approval,
except where under any of the foregoing such noncompliance, failure to receive required permits, licenses or other approvals or
failure to comply with the terms and conditions of such permits, licenses or approvals would not, singly or in the aggregate, have
a material adverse effect on the Company and its subsidiaries, taken as a whole.

 

(r)          The
Company is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof
as described in the Final Memorandum will not be, required to register as an “investment company” as such term is defined
in the Investment Company Act of 1940, as amended (the “Investment Company Act”).

 

    5 

     

    

 

(s)          Neither
the Company, any of the Guarantors nor any of their respective affiliates (as defined in Rule 501(b) of Regulation D under
the Securities Act, an “Affiliate”) has directly, or through any agent, (i) sold, offered for sale, solicited
offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which is or will be integrated
with the sale of the Securities in a manner that would require the registration under the Securities Act of the Securities or (ii) offered,
solicited offers to buy or sold the Securities by any form of general solicitation or general advertising (as those terms are used
in Regulation D under the Securities Act) or in any manner involving a public offering within the meaning of Section 4(a)(2) of
the Securities Act.

 

(t)          It
is not necessary in connection with the offer, sale and delivery of the Securities to the Initial Purchaser in the manner contemplated
by this Agreement to register the Securities under the Securities Act or to qualify the Indenture under the Trust Indenture Act
of 1939, as amended.

 

(u)          The
Securities satisfy the requirements set forth in Rule 144A(d)(3) under the Securities Act.

 

(v)         Neither
the Company, any of the Guarantors nor any of their respective subsidiaries or affiliates, nor to the Company’s knowledge,
any director, officer, employee, agent or representative of the Company, the Guarantors or of any of their respective subsidiaries
or affiliates, has taken or will take any action in furtherance of an offer, payment, promise to pay, or authorization or approval
of the payment or giving of money, property, gifts or anything else of value, directly or indirectly, to any “government
official” (including any officer or employee of a government or government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or
party official or candidate for political office) to influence official action or secure an improper advantage; and the Company,
the Guarantors and their respective subsidiaries and affiliates have conducted their businesses in compliance with applicable anti-corruption
laws and have instituted and maintain and will continue to maintain policies and procedures designed to promote and achieve compliance
with such laws and with the representation and warranty contained herein.

 

(w)          The
operations of the Company and its subsidiaries are and have been conducted at all times in material compliance with all applicable
financial recordkeeping and reporting requirements, including those of the Bank Secrecy Act, as amended by Title III of the Uniting
and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT
Act), and the applicable anti-money laundering statutes of jurisdictions where the Company and its subsidiaries conduct business,
the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced
by any governmental agency (collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding
by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Anti-Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.

 

    6 

     

    

 

(x)          (i)
Neither the Company, nor any of its subsidiaries nor, to the Company’s knowledge, any of their respective directors, officers,
employees, agents, affiliates or representatives, is an individual or entity (“Person”) that is, or is owned
or controlled by a Person that is:

 

      (A) the subject of any sanctions
administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control (“OFAC”),
the United Nations Security Council (“UNSC”), the European Union (“EU”), Her Majesty’s
Treasury (“HMT”), or other relevant sanctions authority (collectively, “Sanctions”); nor

 

     (B) located, organized or resident
in a country or territory that is the subject of Sanctions (including, without limitation, Burma/Myanmar, Cuba, Iran, Libya, North
Korea, Sudan and Syria).

 

             (ii) The Company and its subsidiaries will
not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to
any subsidiary, joint venture partner or other Person:

 

     (A) to fund or facilitate any activities
or business of or with any Person or in any country or territory that, at the time of such funding or facilitation, is the subject
of Sanctions; or

 

    (B) in any other manner that will
result in a violation of Sanctions by any Person (including any Person participating in the offering, whether as underwriter, advisor,
investor or otherwise).

 

            (iii) For the past five years, the Company
and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in, and will not engage in, any dealings or transactions
with any Person, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.

 

(y)          The
Company and each of its subsidiaries have filed all federal, state, local and foreign tax returns required to be filed through
the date of this Agreement or have requested extensions thereof (except where the failure to file would not, individually or in
the aggregate, have a material adverse effect) and have paid all taxes required to be paid thereon (except for cases in which the
failure to file or pay would not have a material adverse effect, or, except as currently being contested in good faith and for
which reserves required by U.S. GAAP have been created in the financial statements of the Company or the Guarantors, as applicable),
and no tax deficiency has been determined adversely to the Company or any of its subsidiaries which has had (nor does the Company
or any of its subsidiaries have any notice or knowledge of any tax deficiency which could reasonably be expected to be determined
adversely to the Company or its subsidiaries and which could reasonably be expected to have) a material adverse effect.

 

    7 

     

    

 

(z)          The
Company and each of its subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles
and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or
specific authorization; and (iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences. Except as described in the Time of Sale Prospectus, since
the end of the Company’s most recent audited fiscal year, there has been (i) no material weakness in the Company’s
or Guarantors’ internal control over financial reporting (whether or not remediated) and (ii) no change in the Company’s
or Guarantors’ internal control over financial reporting that has materially affected, or is reasonably likely to materially
affect, the Company’s or Guarantors’ internal control over financial reporting.

 

2.          Agreements
to Sell and Purchase. The Company hereby agrees to sell to the Initial Purchaser, and the Initial Purchaser, upon the basis
of the representations and warranties herein contained, but subject to the conditions hereinafter stated, agrees to purchase from
the Company $16,000,000 principal amount of Notes at a purchase price of 92.75% of the principal amount thereof (the “Purchase
Price”) plus accrued interest, if any, to the Closing Date, and the Guarantors agree to issue the Guarantee to be affixed
to the Notes.

 

3.          Terms
of Offering. The Initial Purchaser has advised the Company that the Initial Purchaser will make an offering of the Securities
purchased by the Initial Purchaser hereunder as soon as practicable after this Agreement is entered into as, in the Initial Purchaser’s
judgment, is advisable.

 

4.          Payment
and Delivery. Payment for the Securities shall be made by the Initial Purchaser to the Company in federal or other funds immediately
available in New York City against delivery of such Securities for the account of the Initial Purchaser at 10:00 a.m., New York
City time, on September 28, 2016, or at such other time on the same or such other date, not later than September 30, 2016, as shall
be designated in writing by the Initial Purchaser. The time and date of such payment are hereinafter referred to as the “Closing
Date.”

 

The Securities shall be delivered in global
form, with the Guarantee affixed to the Notes, not later than one full business day prior to the Closing Date. The Securities shall
be deposited with the Trustee as custodian for The Depository Trust Company (“DTC”) and registered in the name
of Cede & Co., as nominee for DTC, for the account of the Initial Purchaser, with any transfer taxes payable in connection
with the transfer of the Securities to the Initial Purchaser duly paid, against payment of the Purchase Price therefor plus accrued
interest, if any, to the date of payment and delivery.

 

    8 

     

    

 

5.          Conditions
to the Initial Purchaser’s Obligation. The obligation of the Initial Purchaser to purchase and pay for the Securities
on the Closing Date is subject to the following conditions:

 

(a)          Subsequent
to the execution and delivery of this Agreement and prior to the Closing Date, there shall not have occurred any actual event,
circumstance or change having a material adverse effect, or a development involving a reasonably likely prospective material adverse
effect, on the business, condition (financial or otherwise) or results of operations of the Company and its subsidiaries, taken
as a whole, from that set forth in the Time of Sale Memorandum provided to the prospective purchasers of the Securities that, in
the Initial Purchaser’s reasonable determination, is material and adverse and that makes it, in the Initial Purchaser’s
reasonable determination, impracticable to market the Securities on the terms and in the manner contemplated in the Time of Sale
Memorandum.

 

(b)          The
Initial Purchaser shall have received on the Closing Date a certificate, dated the Closing Date and signed by an executive officer
of each of the Company and the Guarantors, to the effect set forth in Section 5(a) and to the effect that the representations
and warranties of the Company and the Guarantors contained in this Agreement are true and correct as of the Closing Date (except
to the extent that such representations and warranties speak as of another date, in which case, such representations and warranties
shall be true and correct as of such other date) and that the Company and the Guarantors have complied with all of the agreements
and satisfied all of the conditions on its part to be performed or satisfied hereunder on or before the Closing Date.

 

The officer signing and delivering
such certificate may rely upon the best of his or her knowledge as to proceedings threatened.

 

(c)          The
Initial Purchaser shall have received on the Closing Date, the following:

 

(i)          the
Indenture, duly executed and delivered by the Company, the Guarantors and the Trustee;

 

(ii)         the
Warrant Agreement, duly executed and delivered by the Company and the Warrant Agent; and

 

(iii)        the
Registration Rights Agreement, duly executed and delivered by the Company and the Guarantors.

 

(d)          The
Initial Purchaser shall have received on the Closing Date an opinion and negative assurance statement of Manatt, Phelps & Phillips,
LLP, outside counsel for the Company and the Guarantors, dated the Closing Date, to the effect set forth in Exhibit D. Such
opinion and negative assurance statement shall be rendered to the Initial Purchaser at the request of the Company and the Guarantors
and shall so state therein.

 

    9 

     

    

 

(e)          The
Initial Purchaser shall have received on the Closing Date an opinion of O’Melveny & Myers LLP, counsel for the Initial
Purchaser, dated the Closing Date, to the effect set forth in Exhibit E.

 

(f)          The
Initial Purchaser shall have received on each of the date hereof and the Closing Date a letter, dated the date hereof or the Closing
Date, as the case may be, in form and substance satisfactory to the Initial Purchaser, from SingerLewak LLP, independent public
accountants, containing statements and information of the type ordinarily included in accountants’ “comfort letters”
to underwriters with respect to the financial statements and certain financial information contained in or incorporated by reference
into the Time of Sale Memorandum and the Final Memorandum; provided that the letter delivered on the Closing Date shall
use a “cut-off date” not earlier than the date hereof.

 

6.          Covenants
of the Company and the Guarantors. The Company and the Guarantors, jointly and severally, covenant with the Initial Purchaser
as follows:

 

(a)          To
furnish to the Initial Purchaser in New York City, without charge, prior to 10:00 a.m. New York City time on the business
day next succeeding the date of this Agreement and during the period mentioned in Section 6(d) or (e), as many
copies of the Final Memorandum and any supplements and amendments thereto as the Initial Purchaser may reasonably request.

 

(b)          Before
amending or supplementing the Preliminary Memorandum, the Time of Sale Memorandum or the Final Memorandum, to furnish to the Initial
Purchaser a copy of each such proposed amendment or supplement and not to use any such proposed amendment or supplement to which
the Initial Purchaser objects.

 

(c)          To
furnish to the Initial Purchaser a copy of each proposed Additional Written Offering Communication to be prepared by or on behalf
of, used by, or referred to by the Company or the Guarantors and not to use or refer to any proposed Additional Written Offering
Communication to which the Initial Purchaser reasonably objects.

 

(d)          If
the Time of Sale Memorandum is being used to solicit offers to buy the Securities at a time when the Final Memorandum is not yet
available to prospective purchasers and any event shall occur or condition exist as a result of which it is necessary to amend
or supplement the Time of Sale Memorandum in order to make the statements therein, in the light of the circumstances, not misleading,
or if, in the opinion of counsel for the Initial Purchaser, it is necessary to amend or supplement the Time of Sale Memorandum
to comply with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchaser and to any dealer
upon request, either amendments or supplements to the Time of Sale Memorandum so that the statements in the Time of Sale Memorandum
as so amended or supplemented will not, in the light of the circumstances when delivered to a prospective purchaser, be misleading
or so that the Time of Sale Memorandum, as amended or supplemented, will comply with applicable law.

 

    10 

     

    

 

(e)          If,
during such period after the date hereof and prior to the date on which all of the Securities shall have been sold by the Initial
Purchaser, any event shall occur or condition exist as a result of which it is necessary to amend or supplement the Final Memorandum
in order to make the statements therein, in the light of the circumstances when the Final Memorandum is delivered to a purchaser,
not misleading, or if, in the opinion of counsel for the Initial Purchaser, it is necessary to amend or supplement the Final Memorandum
to comply with applicable law, forthwith to prepare and furnish, at its own expense, to the Initial Purchaser, either amendments
or supplements to the Final Memorandum so that the statements in the Final Memorandum as so amended or supplemented will not, in
the light of the circumstances when the Final Memorandum is delivered to a purchaser, be misleading or so that the Final Memorandum,
as amended or supplemented, will comply with applicable law.

 

(f)          To
furnish such information as may be reasonably required and otherwise to cooperate with the Initial Purchaser to qualify the Securities
for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Initial Purchaser shall reasonably request;
provided, however, that the Company shall not be required to qualify as a foreign corporation or to consent to the service
of process under the laws of, or subject itself to taxation as doing business in, any such state or other jurisdiction (except
service of process with respect to the offering and sale of the Securities).

 

(g)          To
apply the net proceeds from the sale of the Securities in accordance with the statements under the caption “Use of Proceeds”
in the Preliminary Memorandum, the Time of Sale Memorandum and the Final Memorandum.

 

    11 

     

    

 

(h)          Whether
or not the transactions contemplated in this Agreement are consummated or this Agreement is terminated, to pay or cause to be paid
all expenses incident to the performance of its obligations under this Agreement, including: (i) the fees, disbursements and expenses
of the Company’s and Guarantors’ counsel and the Company’s and Guarantors’ accountants in connection with
the issuance and sale of the Securities and all other fees or expenses in connection with the preparation of the Preliminary Memorandum,
the Time of Sale Memorandum, the Final Memorandum, any Additional Written Offering Communication prepared by or on behalf of, used
by, or referred to by the Company or the Guarantors and any amendments and supplements to any of the foregoing, including all printing
costs associated therewith, and the delivering of copies thereof to the Initial Purchaser, in the quantities herein above specified,
(ii) all costs and expenses related to the transfer and delivery of the Securities to the Initial Purchaser, including any transfer
or other taxes payable thereon, (iii) the cost of printing or producing any Blue Sky or legal investment memorandum in connection
with the offer and sale of the Securities under state securities laws and all expenses in connection with the qualification of
the Securities for offer and sale under state securities laws as provided in Section 6(f) hereof, including filing
fees and the reasonable fees and disbursements of counsel for the Initial Purchaser, in connection with such qualification and
in connection with the Blue Sky or legal investment memorandum, (iv) any fees charged by rating agencies for the rating of the
Securities, (v) the fees and expenses, if any, incurred in connection with the admission of the Securities for trading any appropriate
market system, (vi) the costs and charges of the Trustee and any transfer agent, registrar or depositary, (vii) the cost of the
preparation, issuance and delivery of the Securities, (viii) the costs and expenses of the Company and the Guarantors relating
to investor presentations on any “road show” undertaken in connection with the marketing of the offering of the Securities,
including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses
associated with production of road show slides and graphics, fees and expenses of any consultants engaged in connection with road
show presentations with the prior approval of the Company or the Guarantors, travel and lodging expenses of the representatives
and officers of the Company and the Guarantors and any such consultants, and the cost of any aircraft chartered in connection with
any road show, (ix) the document production charges and expenses associated with printing this Agreement and (x) all other cost
and expenses incident to the performance of the obligations of the Company and the Guarantors hereunder for which provision is
not otherwise made in this Section 6. It is understood, however, that except as provided in this Section 6 (and subject
to the aggregate limit of $100,000 for out-of-pocket expenses reimbursed by the Company to the Initial Purchaser pursuant to this
Section 6), Section 8, and the last paragraph of Section 10, the Initial Purchaser will pay all
of their costs and expenses, including fees and disbursements of their counsel, transfer taxes payable on resale of any of the
Securities by them and any advertising expenses connected with any offers they may make.

 

(i)          Neither
the Company, the Guarantors nor any of their respective Affiliates will sell, offer for sale or solicit offers to buy or otherwise
negotiate in respect of any security (as defined in the Securities Act) which could be integrated with the sale of the Securities
in a manner which would require the registration under the Securities Act of the Securities.

 

(j)          Not
to solicit any offer to buy or offer or sell the Securities or the Underlying Securities by means of any form of general solicitation
or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering
within the meaning of Section 4(a)(2) of the Securities Act.

 

(k)          While
any of the Securities or the Underlying Securities remain “restricted securities” within the meaning of the Securities
Act, to make available, upon request, to any seller of such Securities the information specified in Rule 144A(d)(4) under
the Securities Act, unless the Company is then subject to Section 13 or 15(d) of the Exchange Act.

 

    12 

     

    

 

(l)          During
the period of two years after the Closing Date, the Company will not be, nor will it become, an open-end investment company, unit
investment trust or face-amount certificate company that is or is required to be registered under Section 8 of the Investment Company
Act.

 

(m)          Not
to take any action prohibited by Regulation M under the Exchange Act in connection with the distribution of the Securities
contemplated hereby.

 

The Company also agrees that, without the
prior written consent of the Initial Purchaser, it will not, during the period ending 90 days after the date of the Final Memorandum
( the “Restricted Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose
of, directly or indirectly, any shares of common stock of the Company or any securities convertible into or exercisable or exchangeable
for common stock of the Company or (2) enter into any swap or other arrangement that transfers to another, in whole or in part,
any of the economic consequences of ownership of the common stock of the Company, whether any such transaction described in clause
(1) or (2) above is to be settled by delivery of common stock or such other securities, in cash or otherwise. The foregoing
sentence shall not apply to (a) the sale of the Securities under this Agreement, (b) the issuance by the Company of any shares
of common stock upon the exercise of an option or warrant or the conversion of a security outstanding on the date hereof as disclosed
in the Company’s filings with the Commission, (c) issuances of options or grants of restricted stock under the Company’s
stock option and incentive plans, or (d) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for
the transfer of shares of common stock, provided that (i) such plan does not provide for the transfer of common stock
during the Restricted Period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required
of or voluntarily made by the Company regarding the establishment of such plan, such announcement or filing shall include a statement
to the effect that no transfer of common stock may be made under such plan during the Restricted Period.

 

7.          Offering
of Securities; Restrictions on Transfer. The Initial Purchaser represents and warrants that the Initial Purchaser is a qualified
institutional buyer as defined in Rule 144A under the Securities Act (a “QIB”). The Initial Purchaser agrees
with the Company that (i) it will not solicit offers for, or offer or sell, such Securities by any form of general solicitation
or general advertising (as those terms are used in Regulation D under the Securities Act) or in any manner involving a public offering
within the meaning of Section 4(a)(2) of the Securities Act and (ii) it will solicit offers for such Securities only from,
and will offer such Securities only to, persons that it reasonably believes to be (1) QIBs or (2) other institutional accredited
investors (as defined in Rule 501(a)(1), (2), (3) or (7) under the Securities Act (“institutional accredited investors”)
that, prior to their purchase of the Securities, deliver to the Initial Purchaser a letter containing the representations and agreements
set forth in a representational letter that, in either case, in purchasing such Securities are deemed to have represented and agreed
as provided in the Final Memorandum under the caption “Transfer Restrictions”.

 

    13 

     

    

 

8.          Indemnity
and Contribution. (a) The Company and the Guarantors, jointly and severally, agree to indemnify and hold harmless the Initial
Purchaser, each person, if any, who controls the Initial Purchaser within the meaning of either Section 15 of the Securities
Act or Section 20 of the Exchange Act, and each affiliate of the Initial Purchaser within the meaning of Rule 405 under
the Securities Act from and against any and all losses, claims, damages and liabilities (including, without limitation, any legal
or other expenses reasonably incurred in connection with defending or investigating any such action or claim) caused by any untrue
statement or alleged untrue statement of a material fact contained in the Preliminary Memorandum, the Time of Sale Memorandum or
any amendment or supplement thereto, any Additional Written Offering Communication prepared by or on behalf of, used by, or referred
to by the Company or any of the Guarantors, any “road show” as defined in Rule 433(h) under the Securities Act (a “road
show”) or the Final Memorandum or any amendment or supplement thereto, or caused by any omission or alleged omission to state
therein a material fact necessary to make the statements therein in the light of the circumstances under which they were made not
misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission or
alleged untrue statement or omission based upon information relating to the Initial Purchaser furnished to the Company or any of
the Guarantors in writing by the Initial Purchaser expressly for use therein.

 

(b)          The
Initial Purchaser agrees to indemnify and hold harmless the Company and the Guarantors, their directors, their officers and each
person, if any, who controls the Company within the meaning of either Section 15 of the Securities Act or Section 20
of the Exchange Act to the same extent as the foregoing indemnity from the Company and the Guarantors to the Initial Purchaser,
but only with reference to information relating to the Initial Purchaser furnished to the Company or the Guarantors in writing
by the Initial Purchaser expressly for use in the Preliminary Memorandum, the Time of Sale Memorandum, any Additional Written Offering
Communication prepared by or on behalf of, used by or referred to by the Company, Guarantors, road show, or the Final Memorandum
or any amendment or supplement thereto.

 

    14 

     

    

 

(c)          In
case any proceeding (including any governmental investigation) shall be instituted involving any person in respect of which indemnity
may be sought pursuant to Section 8(a) or 8(b), such person (the “indemnified party”) shall
promptly notify the person against whom such indemnity may be sought (the “indemnifying party”) in writing and
the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified
party to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the
fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the
right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless
(i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named
parties to any such proceeding (including any impleaded parties) include both the indemnifying party and the indemnified party
and representation of both parties by the same counsel shall have been reasonably concluded (based on the advice of counsel) to
be inappropriate due to an actual conflict between them. It is understood that the indemnifying party shall not, in respect of
the legal expenses of any indemnified party in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all such indemnified
parties and that all such fees and expenses shall be reimbursed as they are incurred. Such firm shall be designated in writing
by the Initial Purchaser, in the case of parties indemnified pursuant to Section 8(a), and by the Company, in the case
of parties indemnified pursuant to Section 8(b). The indemnifying party shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff,
the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement
or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party
to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph,
the indemnifying party agrees that it shall be liable for any settlement of any proceeding effected without its written consent
if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and
(ii) such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the date
of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement
of any pending or threatened proceeding in respect of which any indemnified party is or could have been a party and indemnity could
have been sought hereunder by such indemnified party, unless such settlement includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such proceeding.

 

    15 

     

    

 

(d)          To
the extent the indemnification provided for in Section 8(a) or 8(b) is unavailable to an indemnified party or
insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each indemnifying party under such
paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified
party as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative
benefits received by the Company and the Guarantors on the one hand and the Initial Purchaser on the other hand from the offering
of the Securities or (ii) if the allocation provided by Section 8(d)(i) above is not permitted by applicable law, in
such proportion as is appropriate to reflect not only the relative benefits referred to in Section 8(d)(i) above but
also the relative fault of the Company and the Guarantors on the one hand and of the Initial Purchaser on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company and the Guarantors on the one hand and the Initial Purchaser on the
other hand in connection with the offering of the Securities shall be deemed to be in the same respective proportions as the net
proceeds from the offering of the Securities (before deducting expenses) received by the Company and the Guarantors and the total
discounts and commissions received by the Initial Purchaser bear to the aggregate offering price of the Securities. The relative
fault of the Company and the Guarantors on the one hand and of the Initial Purchaser on the other hand shall be determined by reference
to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to
state a material fact relates to information supplied by the Company or the Guarantors on the one hand, or by the Initial Purchaser
on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent
such statement or omission.

 

(e)          The
Company, the Guarantors and the Initial Purchaser agree that it would not be just or equitable if contribution pursuant to this
Section 8 were determined by pro rata allocation or by any other method of allocation that does not take account
of the equitable considerations referred to in Section 8(d). The amount paid or payable by an indemnified party as
a result of the losses, claims, damages and liabilities referred to in Section 8(d) shall be deemed to include, subject
to the limitations set forth above, any legal or other expenses reasonably incurred by such indemnified party in connection with
investigating or defending any such action or claim. Notwithstanding the provisions of this Section 8, the Initial
Purchaser shall not be required to contribute any amount in excess of the amount by which the total price at which the Securities
resold by it in the initial placement of such Securities were offered to investors exceeds the amount of any damages that the Initial
Purchaser has otherwise been required to pay by reason of such untrue statement or alleged untrue statement or omission or alleged
omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for
in this Section 8 are not exclusive and shall not limit any rights or remedies which may otherwise be available to
any indemnified party at law or in equity.

 

(f)          The
indemnity and contribution provisions contained in this Section 8 and the representations, warranties and other statements
of the Company and the Guarantors contained in this Agreement shall remain operative and in full force and effect regardless of
(i) any termination of this Agreement, (ii) any investigation made by or on behalf of the Initial Purchaser, any person controlling
the Initial Purchaser or any affiliate of the Initial Purchaser or by or on behalf of the Company, the Guarantors, their respective
officers or directors or any person controlling the Company or the Guarantors and (iii) acceptance of and payment for any of the
Securities.

 

    16 

     

    

 

9.          Termination.
The Initial Purchaser may terminate this Agreement by notice given to the Company, if after the execution and delivery of this
Agreement and prior to the Closing Date (i) trading generally shall have been suspended or materially limited on, or by, as the
case may be, the NASDAQ Global Market, (ii) a material disruption in securities settlement, payment or clearance services in the
United States or other relevant jurisdiction shall have occurred, (iii) any moratorium on commercial banking activities shall have
been declared by federal, New York State or California State authorities, (iv) the Company shall have received, on or after the
date of this Agreement, any inquiry, notice, complaint or any other communication from a governmental body that, in the reasonable
judgment of the Initial Purchaser, is material and adverse to the Company, or (v) there shall have occurred any event, circumstance
or change having a material adverse effect on the business, condition (financial or otherwise) or results of operations of the
Company and its subsidiaries, taken as a whole, from that set forth in the Time of Sale Memorandum provided to the prospective
purchasers of the Securities that, in the Initial Purchaser’s reasonable determination, is material and adverse and that
makes it, in the Initial Purchaser’s reasonable determination, impracticable to market and sell the Securities on the terms
and in the manner contemplated in the Time of Sale Memorandum.

 

10.         Effectiveness.
This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.

 

If this Agreement shall be terminated by
the Initial Purchaser prior to closing because of any inability, failure or refusal on the part of the Company or any of the Guarantors
to comply with the terms or to fulfill any of the conditions of this Agreement, the Company and the Guarantors will reimburse the
Initial Purchaser for up to $50,000 of out-of-pocket expenses (including the fees and disbursements of its counsel) reasonably
incurred by the Initial Purchaser in connection with this Agreement or the offering contemplated hereunder.

 

11.       Entire
Agreement.

 

(a)          This Agreement, together
with any contemporaneous written agreements and any prior written agreements (to the extent not superseded by this Agreement) that
relate to the offering of the Securities, represents the entire agreement between the Company, the Guarantors and the Initial Purchaser
with respect to the preparation of the Preliminary Memorandum, the Time of Sale Memorandum, the Final Memorandum, the conduct of
the offering, and the purchase and sale of the Securities.

 

(b)          The
Company and the Guarantors acknowledge that in connection with the offering of the Securities: (i) the Initial Purchaser has acted
at arms’-length, is not an agent of, and owes no fiduciary duties to, the Company, the Guarantors or any other person, (ii) the
Initial Purchaser owes the Company and the Guarantors only those duties and obligations set forth in this Agreement and prior written
agreements (to the extent not superseded by this Agreement) if any, and (iii) the Initial Purchaser may have interests that differ
from those of the Company or the Guarantors. The Company and the Guarantors waive to the full extent permitted by applicable law
any claims it may have against the Initial Purchaser arising from an alleged breach of fiduciary duty in connection with the offering
of the Securities.

 

    17 

     

    

 

12.         Counterparts.
This Agreement may be signed in two or more counterparts, each of which shall be an original, with the same effect as if the
signatures thereto and hereto were upon the same instrument.

 

13.         Applicable
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York.

 

14.         Headings.
The headings of the sections of this Agreement have been inserted for convenience of reference only and shall not be deemed
a part of this Agreement.

 

15.         Notices.
All communications hereunder shall be in writing and effective only upon receipt and:

 

(a)          if
to the Initial Purchaser shall be delivered, mailed or sent to BTIG, LLC, 600 Montgomery Street, 6th Floor, San Francisco, CA 94111,
Attn: Steve Druskin, Esq., with a copy to O’Melveny & Myers LLP, 2 Embarcadero Center, 27th Floor, San Francisco, CA
94111, Attn: Peter T. Healy, Esq.

 

(b)          if
to the Company or any of the Guarantors shall be delivered, mailed or sent to Digital Turbine, Inc., 1300 Guadalupe Street, Suite
302, Austin, TX 78701, Attn: Chief Executive Officer, with a copy to Manatt, Phelps & Phillips, LLP, 11355 W. Olympic Blvd.,
Los Angeles, CA 90064, Attn: Ben Orlanski, Esq.

 

[Signature Pages Follow]

 

    18 

     

    

 

IN WITNESS WHEREOF, the Company and each
of the Guarantors have caused this Agreement to be duly executed by its authorized person as of this _____ day of September, 2016.

 

	The Company	 
	 	 	 
	DIGITAL TURBINE, INC.	 
	 	 
	By:	 	 
	Name:	William Stone	 
	Title:	Chief Executive Officer	 

 

	Guarantors	 	 
		 	 
	DIGITAL TURBINE USA, INC., a Delaware corporation	 	DIGITAL TURBINE ASIA PACIFIC PTY LTD., a company formed under the laws of Australia
	 	 	 	 
	By: 	 	 	By:	 
	Name:	 	 	Name:
	Title:	 	 	Title:
	 	 	 	 
	DIGITAL TURBINE MEDIA, INC., a Delaware corporation	 	 
	 	 	 	 
	By: 	 	 	 
	Name:	William Stone	 	 
	Title: 	Chief Executive Officer	 	 
	 	 	 	 
	DIGITAL TURBINE (EMEA) LTD., a company formed under the laws of Israel	 	 
	 	 	 	 
	By: 	 	 	 
	Name:	 	 	 
	Title:	 	 	 
	 	 	 	 
	By: 	 	 	 
	Name:	 	 	 
	Title:	 	 	 

 

Company and Guarantor Signature Page to Convertible Note
Initial Purchaser Agreement

 

     

     

    

 

IN WITNESS WHEREOF, the undersigned Initial
Purchaser has caused this Agreement to be duly executed by its authorized person as of this ______ day of September, 2016.

 

	 	Initial Purchaser

BTIG, LLC
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

Initial Purchaser
Signature Page to Convertible Note Initial Purchaser Agreement

 

     

     

    

 

Schedule I

  

Time of Sale Memorandum

 

		1.	Preliminary Memorandum issued September 23, 2016

 

		2.	orally communicated pricing information, as follows:

 

		-	Closing price of Company’s common stock on September
22, 2016: $1.24 (the latest market value of the Company’s common stock prior to the time of pricing)

 

		-	Interest rate of Notes: 8.75%

 

		-	Conversion price of Notes: $1.364

 

		-	Purchasers of Notes to receive warrants subject to the
Warrant Agreement to purchase 256.60 shares of common stock for every $1,000 of Note purchased at an exercise price of $1.364
per share.

 

    	 	I-1	 

     

    

 

EXHIBIT
A

 

FORM OF INDENTURE

 

    	 	A-1	 

     

    

 

EXHIBIT
B

 

FORM OF WARRANT AGREEMENT

 

    	 	B-1	 

     

    

 

EXHIBIT C

 

FORM OF REGISTRATION RIGHTS AGREEMENT

 

    	 	C-1	 

     

    

 

EXHIBIT D

 

OPINION OF MANATT, PHELPS &
PHILLIPS, LLP

 

 

    	 	D-1	 

     

    

 

EXHIBIT
E

 

OPINION OF O’MELVENY &
MYERS LLP

 

 

    	 	E-1imgn_exhibit_101

		

			 

		

		
			Exhibit 10.1
		

		
			 
		

		
			 
		

		
			 
		

		
			IMMUNOGEN INC.
		

		
			SEVERANCE PAY PLAN
		

		
			AND
		

		
			SUMMARY PLAN DESCRIPTION
		

		
			FOR VICE PRESIDENTS AND HIGHER
		

		
			As amended through September 23, 2016
		

		
			 
		

		
			 
		

		
			 
		

		
			

		 

		

			ImmunoGen, Inc. Severance Pay Plan

		

		

			for Vice Presidents and Higher

		

		

			Amended as of  September 23, 2016

		

 

		

			 

		

		

		
			TABLE OF CONTENTS
		

			
					
						I. 

					
					
						Purpose

					
					
						1

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						II. 

					
					
						Eligibility

					
					
						1

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						III. 

					
					
						Severance Benefits

					
					
						3

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						IV. 

					
					
						Conditions Governing Payment

					
					
						5

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						V. 

					
					
						Reemployment

					
					
						6

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						VI. 

					
					
						Plan Continuance

					
					
						6

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						VII. 

					
					
						Administration of the Plan

					
					
						6

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						VIII. 

					
					
						Claim and Claim Appeal Procedures

					
					
						6

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						IX. 

					
					
						Your Rights Under ERISA

					
					
						8

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						X. 

					
					
						Tax Information

					
					
						9

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						XI. 

					
					
						Severability

					
					
						10

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						XII. 

					
					
						General Information

					
					
						11

				

		
			 
		

		
			 
		

		
			

		 

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Amended as of  September 23, 2016

		

 

		

			 

		

		

		
			IMMUNOGEN INC.
		

		
			SEVERANCE PAY PLAN 
		

		
			AND
		

		
			SUMMARY PLAN DESCRIPTION
		

		
			FOR VICE PRESIDENTS AND HIGHER
		

		
			(As amended through September 23, 2016)
		

			
	
			
				 I.
			

			
	
			
			Purpose

		
			The purpose of the ImmunoGen, Inc. Severance Pay Plan for Vice Presidents and Higher (the “Plan”) is to provide, in the sole discretion of ImmunoGen, Inc. (the “Company”), a period of continued income and benefits (“Severance Benefits”) to eligible employees who serve in certain positions as designated by the Company, and whose employment with the Company is involuntarily terminated without Cause (as defined herein).
		

		
			 
		

		
			The Plan is designed to be an unfunded “employee welfare benefit plan,” as defined in Section 3(1) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and, accordingly, the Plan is governed by ERISA.  This document constitutes both the Plan document and the summary plan description required under ERISA.
		

		
			 
		

			
	
			
				 II.
			

			
	
			
			Eligibility

			
	
			
				 A.
			

			
	
			
			For purposes of this Plan, the term “Eligible Employee” means an employee of the Company:

			
	
			
				 1)
			

			
	
			
			who holds the position of Vice President and higher; and

			
	
			
				 2)
			

			
	
			
			whose employment with the Company is terminated by the Company without Cause.

			
	
			
				 B.
			

			
	
			
			For the avoidance of doubt, unless the Company provides otherwise in writing, Severance Benefits will NOT be paid to an employee:

			
	
			
				 1)
			

			
	
			
			terminating employment voluntarily;

			
	
			
				 2)
			

			
	
			
			on a leave of absence, whether approved or unapproved; 

			
	
			
				 3)
			

			
	
			
			terminated by the Company for Cause.  For purposes of this Plan, “Cause” means that the employee has, as determined by the Company in its sole discretion: (i) willfully committed an act or omission that materially harms the Company; (ii) been grossly negligent in the performance of the employee’s duties to the Company; (iii) willfully failed or refused to follow 

		 

		

			1

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

	the lawful and proper directives of the Chief Executive Officer or the Board of Directors of the Company (the “Board”); (iv) been convicted of, or pleaded guilty or nolo contendere, to a felony; (v) committed an act involving moral turpitude that is or is reasonably expected to be injurious to the Company or its reputation; (vi) committed an act relating to the employee’s employment or the Company involving in the good faith judgment of the Board, material fraud or theft; (vii) breached any material provision of any agreement between the employee and the Company or any nondisclosure or non-competition agreement between the employee and the Company, as all of the foregoing may be amended prospectively from time to time; or (viii) breached a material provision of any code of conduct or ethics policy in effect at the Company, as all of the foregoing may be amended prospectively from time to time (each of the foregoing hereinafter referred to as a “Violation”); provided, however, that if a Violation described in clauses (ii), (vii) or (viii) is susceptible of cure, the employee will be afforded a reasonable period (not to exceed twenty (20) business days) after receiving the initial written notice from the Company of such Violation to substantially cure such Violation prior to the Company taking any action to terminate the employee’s employment for Cause;

			
	
			
				 4)
			

			
	
			
			if the employee has been offered another reasonably comparable position with the Company, whether or not the employee accepts such offer; or

			
	
			
				 5)
			

			
	
			
			if the employee is entitled to receive severance compensation under the terms of any separate written agreement, including, without limitation, any change in control severance agreement or employment agreement, between the Company and the employee in connection with the termination of the employee’s employment following a change in control of the Company or otherwise.

		
			For purposes of clause (4) above, whether an offer is “reasonably comparable” will be determined by the Company in its sole reasonable discretion.  The Company shall, but is not necessarily limited to, consider the following factors in making such determination: (a) the change in commute; (b) a comparison of the offered annual base salary against the employee’s then current annual base salary; and (c) whether the employee is reasonably capable of performing the responsibilities of the position by training or experience.
		

			
	
			
				 C.
			

			
	
			
			Notwithstanding any provisions of this Plan to the contrary, the Company shall not be obligated to pay the employee and the employee shall not be eligible to receive any Severance Benefits set forth in Section III unless the employee executes, delivers, and does not revoke a “separation agreement” within the time period set forth in the separation agreement.  The separation agreement generally will include:

			
	
			
				 ·
			

			
	
			
			a release of claims;

			
	
			
				 ·
			

			
	
			
			a non-disparagement agreement;

		
			

		 

		

			2

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

		

			
	
			
				 ·
			

			
	
			
			a non-competition agreement;

			
	
			
				 ·
			

			
	
			
			a non-solicitation agreement; and

			
	
			
				 ·
			

			
	
			
			such other provisions that the Company may require.

		
			 
		

			
	
			
				 III.
			

			
	
			
			Severance Benefits

		
			Provided that an Eligible Employee satisfies all conditions for receipt in accordance with the terms of this Plan, an Eligible Employee shall be entitled to the following Severance Benefits:
		

			
	
			
				 A.
			

			
	
			
			Severance Pay

		
			An Eligible Employee will receive Severance Pay in accordance with the following schedule:
		

			
					
						 

					
					
						 

				
	
					
						Chief Executive Officer

					
					
						18 months

				
	
					
						Executive Officer (as designated by the Board) 

					
					
						12 months

				
	
					
						Vice President (other than Executive Officer)

					
					
						Two (2) weeks of salary for each year of service, subject to a minimum Severance Pay level of 26 weeks and a maximum Severance Pay level of 52 weeks

				

		
			 
		

		
			Severance Pay will be calculated on the basis of the Eligible Employee’s highest annualized base salary in the 12 months preceding the date of termination of employment with the Company (the “Termination Date”).
		

		
			For these purposes, an Eligible Employee who is a Vice President (other than an Executive Officer) is entitled to credit for a year of service for each 12 month period of continuous service commencing on the Eligible Employee’s date of hire (or in the case of an Eligible Employee who has more than one period of service with the Company, the most recent date of hire); provided however, that credit for a full year of service will be given if the Termination Date is six (6) months or more from the most  recent anniversary date of the Eligible Employee’s date of hire (or most recent date of hire as noted above).
		

		
			Severance Pay will be paid by means of salary continuation payments commensurate with the Company’s normal payroll cycles, for the duration of the period described above (the “Severance Period”), to commence as soon as practicable following the effective date of the separation agreement, but no later than sixty (60) days following the Termination Date, subject to the provisions of Section II(C) and Section IV.  In case of the death of an Eligible Employee before the completion of all Severance Payments, any remaining Severance Payments will 

		 

		

			3

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

be paid in a lump sum to the beneficiary or beneficiaries as set forth in the Eligible Employee’s beneficiary designation under the Company’s group life insurance program as in effect on the Eligible Employee’s Termination Date, as soon as administratively feasible, but in no event later than sixty (60) days following the Company’s receipt of notice of the Eligible Employee’s death.  If no such beneficiary designation is in effect on the Termination Date, or if no such designated beneficiary(ies) survive the Eligible Employee, the remaining Severance Payments will be paid to Eligible Employee’s estate.
		

			
	
			
				 B.
			

			
	
			
			Annual Bonus

			
	
			
				 1)
			

			
	
			
			An Eligible Employee will be entitled to receive a payment equal to his or her annual bonus related to the most recently completed fiscal year, determined in accordance with the terms of the Company’s annual bonus program, if not already paid on or prior to the Termination Date.

			
	
			
				 2)
			

			
	
			
			For the fiscal year in which the Eligible Employee’s termination occurs, the Eligible Employee will be entitled to receive 100% of the portion of his or her target annual bonus tied to personal objectives.  With respect to the portion of the annual bonus tied to corporate objectives, the Eligible Employee will be entitled to receive the same percentage as the other participants in the Company’s annual bonus program.  The foregoing notwithstanding, the annual bonus for the fiscal year in which the Eligible Employee’s termination occurs which the Eligible Employee is entitled to receive as described above will be pro-rated to reflect the actual number of days the Eligible Employee was employed during the applicable fiscal year.

		
			Any annual bonus amounts due to the Eligible Employee will be paid to the Eligible Employee at the same time bonuses are paid to other participants in the Company’s annual bonus program.  In case of the death of an Eligible Employee before payment of the annual bonus amounts due to the Eligible Employee, such bonus amounts will be paid to the beneficiary or beneficiaries as set forth in the Eligible Employee’s beneficiary designation under the Company’s group life insurance program as in effect on the Eligible Employee’s Termination Date.  If no such beneficiary designation is in effect on the Termination Date, or if no such designated beneficiary(ies) survive the Eligible Employee, the bonus amounts will be paid to the Eligible Employee’s estate.
		

			
	
			
				 C.
			

			
	
			
			COBRA Premium

		
			If an Eligible Employee timely elects to continue medical and dental coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”), the Company will subsidize such Eligible Employee’s COBRA premium at the same rate the Company subsidizes coverage for similarly situated active employees, as such subsidy may be modified from time-to-time.  In the event that the Company determines that the COBRA premium subsidy is taxable income to Eligible Employees, the income will be reported on Form W-2 as imputed 

		 

		

			4

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

income.  The COBRA premium subsidy will continue for the duration of the Eligible Employee’s Severance Period, or until COBRA ends, if earlier.  Upon the cessation of the COBRA premium subsidy, the Eligible Employee will be entitled to continue his or her medical and/or dental coverage for the duration of the COBRA continuation period, if any, at the Eligible Employee’s own cost.
		

			
	
			
				 D.
			

			
	
			
			Outplacement Services

		
			Outplacement services lasting not less than 6 months will be provided at a level to be determined by the Company in its sole discretion.  If an Eligible Employee fails to commence utilization of the outplacement services provided by the Company within 60 days of his or her Termination Date, the outplacement services shall be forfeited.  In no event will an Eligible Employee be entitled to the cash value of the outplacement services in lieu of the outplacement services.
		

			
	
			
				 IV.
			

			
	
			
			Conditions Governing Payment

			
	
			
				 A.
			

			
	
			
			In addition to the satisfaction of any conditions set forth above, an Eligible Employee will only receive such Severance Benefits if the Company determines that the Eligible Employee has satisfied the following:

			
	
			
				 1)
			

			
	
			
			the Eligible Employee must continue to be actively at work to the satisfaction of the Company through the last day of work designated and as determined by the Company, in its sole discretion, unless the Eligible Employee’s absence is covered by the Company’s paid time off policy, or if the Company, in its sole discretion, has agreed in writing to adjust the Eligible Employee’s last day of work to an earlier date than previously scheduled; and

			
	
			
				 2)
			

			
	
			
			the Eligible Employee must have returned all Company property and settled satisfactorily all expenses owed to the Company.

			
	
			
				 B.
			

			
	
			
			Any Severance Benefits to which the Eligible Employee may be entitled will be offset, in the sole discretion of the Company, by any amounts the Eligible Employee may owe the Company, such as pay for time under the Company’s paid time off policy the Eligible Employee may have been advanced but was not earned at the time of termination, unauthorized or un-reconciled business expenses, and the value of any Company equipment in the Eligible Employee’s possession which the Eligible Employee has not returned to the Company.

			
	
			
				 C.
			

			
	
			
			Any Severance Benefits to which an Eligible Employee may be entitled shall immediately cease upon the determination by the Company that such Eligible Employee violated the terms of the separation agreement or the Proprietary Information, Inventions and Competition Agreement between the Company and the Eligible Employee.

		
			

		 

		

			5

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

		

			
	
			
				 V.
			

			
	
			
			Reemployment

		
			If rehired by the Company, any Severance Benefits to which an Eligible Employee may be entitled shall cease with the payment for the period ending the day immediately preceding the date of rehire.
		

			
	
			
				 VI.
			

			
	
			
			Plan Continuance

		
			The Company expects to continue this Plan indefinitely, but reserves the right to amend or terminate the Plan, or any portion of the Plan, at any time in its sole discretion by action of the Board.  Further, the Company, by action of the Board, reserves the right to modify the benefits set forth in this Plan, or to pay such other benefits as it may, in its sole discretion, deem appropriate, in addition to or in lieu of the benefits set forth in this Plan.  Notwithstanding the above, any amendment or modification to the Plan that decreases benefits available under the Plan will apply only to those employees who have a Termination Date after the effective date of such modification or amendment.
		

			
	
			
				 VII.
			

			
	
			
			Administration of the Plan

		
			The Company, acting through the Head of Human Resources (“HHR”), shall be the Plan Administrator.  The Plan Administrator shall have sole authority and discretion to administer and construe the terms of this Plan, subject to applicable requirements of law.  Without limiting the generality of the foregoing, the Plan Administrator shall have complete discretionary authority to carry out the following powers and duties:
		

			
	
			
				 1)
			

			
	
			
			to make and enforce such rules and regulations as it deems necessary or proper for the efficient administration of the Plan;

			
	
			
				 2)
			

			
	
			
			to interpret and construe the Plan, its interpretations and constructions thereof to be final and conclusive on all persons claiming Severance Benefits under the Plan;

			
	
			
				 3)
			

			
	
			
			to decide all questions, including without limitation, issues of fact, concerning the Plan, including the eligibility of any person to participate in, and receive Severance Benefits under the Plan; and

			
	
			
				 4)
			

			
	
			
			to appoint such agents, counsel, accountants, consultants and other persons as may be required to assist in the administration of the Plan.

			
	
			
				 VIII.
			

			
	
			
			Claim and Claim Appeal Procedures

		
			Employees who are eligible for Severance Payments under this Plan will be notified by the Company.  If you believe that you did not receive the Severance Benefits to which you were entitled, you need to make a claim with the Director, Human Resources Business Partner (the “HR Business Partner”). The HR Business Partner will review and make a decision with respect to your claim within 90 days of receipt of your claim, unless the HR Business Partner determines that special circumstances require an extension of time for processing the claim, in which case you will receive a written notice of the extension before termination of the initial 90-day period.  The 

		 

		

			6

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

extension notice will indicate the special circumstances requiring the extension and the date by which the HR Business Partner expects to render the benefit determination.
		

		
			If any claim is denied in whole or in part, you or your beneficiary will receive written notification within 90 days, including the reasons for the denial; reference to the specific Plan provisions on which the denial was based; information about additional material needed to pursue the claim, if any, and why such material is needed; and an explanation of the claim appeal procedure including a statement of your right to bring a civil action under § 502(a) of ERISA following an adverse benefit determination on appeal.  Within 60 days, you or your beneficiary may submit a written request for reconsideration of the claim to the HHR.
		

		
			You or your representative may submit written comments, documents, records, and other information relating to the claim for Severance Benefits.  Upon request and free of charge, you or your representative may have reasonable access to, and copies of, all documents, records, and other information relevant to your claim for Severance Benefits.
		

		
			The review by the HHR will take into account all comments, documents, records, and other information you submit relating to the claim, without regard to whether such information was submitted or considered in the initial Severance Benefits determination.
		

		
			The HHR will make a decision on your appeal within 60 days after the receipt of the appeal.  If the HHR determines that special circumstances require an extension of time for processing the appeal, you will receive a written notice of the extension before the end of the initial 60-day period.  The extension notice shall indicate the special circumstances requiring the extension and the date by which the Plan expects to render the determination on appeal.
		

		
			If your appeal is denied in whole or in part, you will receive a written notification including the reasons for the denial; reference to the specific Plan provisions on which the denial was based; a statement that you are entitled to receive, upon request and free of charge, reasonable access to, and copies of, all documents, records, and other information relevant to your claim for Severance Benefits; and a statement describing any voluntary appeal procedures offered by the Plan and your right to obtain information about such procedures, as well as a statement of your right to bring a civil action under § 502(a) of ERISA.
		

		
			The HHR will decide whether a hearing will be held on the claim and will notify you at least 14 days before the hearing, if one is to be held.
		

		
			To the extent permitted by law, decisions reached under the claims procedures set forth in this Section VIII shall be final and binding on all parties.  No action (whether at law, in equity or otherwise) shall be brought by or on behalf of any participant or Beneficiary for or with respect to benefits due under this Plan unless the person bringing such action has timely exhausted the Plan’s claim review procedure.  In any such legal action, the claimant may only present evidence and theories which the claimant presented during the claims procedure.  Any claims which the claimant does not in good faith pursue through the review stage of the procedure shall be treated as having been irrevocably waived.  Judicial review of a claimant’s denied claim shall be limited to a determination of whether the denial was an abuse of discretion based on the evidence and theories the claimant presented during the claims procedure.
		

		
			

		 

		

			7

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

		

		
			Any action (whether at law, in equity or otherwise) must be commenced within one (1) year and must be brought in a court of competent jurisdiction sitting in Waltham, Massachusetts.  This one (1) year period shall be computed from the earlier of: (a) the date a final determination denying such benefit, in whole or in part, is issued under the Plan’s claim review procedure; and (b) the date such individual’s cause of action first accrued (as determined under the laws of the Commonwealth of Massachusetts without regard to principles of choice of laws).
		

			
	
			
				 IX.
			

			
	
			
			Your Rights Under ERISA

		
			As a participant in the Plan you are entitled to certain rights and protections under ERISA.  ERISA provides that all Plan participants shall be entitled to:
		

			
	
			
				 A.
			

			
	
			
			Receive Information About Your Plan and Benefits

			
	
			
				 1)
			

			
	
			
			Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites and union halls, all documents governing the Plan, including insurance contracts, and a copy of the latest annual report (Form 5500 Series) filed by the Plan with the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration.

			
	
			
				 2)
			

			
	
			
			Obtain, upon written request to the Plan Administrator, copies of documents governing the operation of the Plan, including insurance contracts, and copies of the latest annual report (Form 5500 Series) and updated summary plan description.  The Plan Administrator may make a reasonable charge for the copies.

			
	
			
				 B.
			

			
	
			
			Prudent Actions by Plan Fiduciaries

		
			In addition to creating rights for Plan participants, ERISA imposes duties upon the people who are responsible for the operation of the Plan.  The people who operate your plan, called “fiduciaries” of the Plan, have a duty to do so prudently and in your interest and that of other Plan participants and beneficiaries.  No one, including your employer or any other person, may fire you or otherwise discriminate against you in any way to prevent you from obtaining a welfare benefit or exercising your rights under ERISA.
		

			
	
			
				 C.
			

			
	
			
			Enforce Your Rights

		
			If your claim for a welfare benefit is denied or ignored, in whole or in part, you have a right to know why this was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain time schedules.
		

		
			Under ERISA, there are steps you can take to enforce the above rights.  For instance, if you request a copy of Plan documents or the latest annual report from the Plan and do not receive them within 30 days, you may file suit in a federal court.  In such a case, the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials, unless the materials were not sent because of reasons beyond the control of the Plan Administrator.  

		 

		

			8

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

If you have a claim for benefits which is denied or ignored, in whole or in part, you may file suit in a state or federal court.  If it should happen that Plan fiduciaries misuse the Plan’s money, or if you are discriminated against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a federal court.  The court will decide who should pay court costs and legal fees.  If you are successful, the court may order the person you have sued to pay these costs and fees.  If you lose, the court may order you to pay these costs and fees, for example, if it finds your claim is frivolous.
		

			
	
			
				 D.
			

			
	
			
			Assistance with Your Questions

		
			If you have questions about the Plan, you should contact the Plan Administrator.  If you have any questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor, listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration, U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210.  You may also obtain certain publications about your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.
		

			
	
			
				 X.
			

			
	
			
			Tax Information

		
			It is intended that this Plan: (i) be exempt from the requirements of Section 409A of the Internal Revenue Code (the “Code”) of 1986 (“Section 409A”) to the maximum extent possible (under the short-term deferral rules of Treasury Regulation Section 1.409A-1(b)(4)(i) and/or the exemption for involuntary terminations under the separation pay plan rules of Treasury Regulation Section 1.409A-1(b)(9)(iii)).
		

		
			If this Plan is not exempt from the requirements of Section 409A of the Code, or to the extent the Plan is not so exempt, it is intended that the Plan comply with the requirements of Section 409A of the Code and the Plan shall be interpreted, operated and administered accordingly, including:
		

		
			(i)The phrase termination of employment, or any derivation thereof, shall mean a “separation from service” within the meaning of Code Section 409A.
		

		
			(ii)To the extent that this Plan requires that a payment shall be made following the execution of a waiver and release agreement, such payment or payments will only be made if the waiver and release agreement is executed prior to the 60th day following the Termination Date; provided, that if this 60 day period commences in one tax year and ends in the next tax year, no payment which is the subject of such waiver and release agreement may be made or commence (in the case of a series of payments), until the second of the tax years.  The Employee may not designate the year of such payment.
		

		
			(iii)To the extent that this Plan provides for the reimbursement of specified expenses incurred by an Eligible Employee, such reimbursement shall be made in accordance with the provisions of this Plan, but in no event later than the last day of the Eligible Employee’s taxable year following the taxable year in which the expense was 

		 

		

			9

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

incurred.  The amount of expenses eligible for reimbursement in any taxable year of the Eligible Employee shall not affect the amount of expenses to be reimbursed or provided in any other year (except in the case of maximum benefits to be provided under a medical reimbursement arrangement, if applicable).
		

		
			(iv)Payments in respect of an Eligible Employee’s termination of employment under this Plan are designated as separate payments for purposes of the short-term deferral rules under Treasury Regulation Section 1.409A-1(b)(4)(i)(F) and the exemption for involuntary terminations under separation pay plans under Treasury Regulation Section 1.409A-1(b)(9)(iii).  As a result, (a) any payments that become vested as a result of the Eligible Employee’s termination of employment under this Plan that are made on or before the 15th day of the third month of the later of the calendar year or Company fiscal year following the calendar or fiscal year of the Eligible Employee’s termination of employment, and (b) any additional payments that are made on or before the last day of the second calendar year following the year of the Eligible Employee’s termination of employment and do not exceed the lesser of two times base salary or two times the limit under Code Section 401(a)(17) then in effect, and (c) the payment of medical expenses within the applicable COBRA period, are exempt from the requirements of Code Section 409A.
		

		
			(v)Notwithstanding any other provision with respect to the timing of payments under Section III, if, at the time of Eligible Employee’s termination, Eligible Employee is deemed to be a “specified employee” (within the meaning of Section 409A, and any successor statute, regulation and guidance thereto) of the Company, then solely to the extent necessary to comply with the requirements of Section 409A, any payments to which Eligible Employee may become entitled under Section III which are subject to Section 409A (and not otherwise exempt from its application) will be withheld until the first (1st) business day of the seventh (7th) month following the Termination Date, at which time Eligible Employee shall be paid an aggregate amount equal to the accumulated, but unpaid, payments otherwise due to Eligible Employee under the terms of Section III.
		

		
			Notwithstanding anything in this Plan to the contrary, the Company does not guarantee the tax treatment of any Severance Benefits under this Plan, including without limitation pursuant to the Code, federal, state or local tax laws or regulations.
		

			
	
			
				 XI.
			

			
	
			
			Severability

		
			In the case any provision of the Plan is determined to be illegal or invalid for any reason, such illegality or invalidity will not affect the remaining parts of the Plan, but the Plan will be construed and enforced as if such illegal or invalid provision never existed.
		

		
			

		 

		

			10

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

		

 

		

			 

		

		

			
	
			
				 XII.
			

			
	
			
			General Information

			
					
						 

					
					
						 

				
	
					
						Plan Name:

					
					
						ImmunoGen, Inc. Severance Pay Plan for Vice Presidents and Higher

				
	
					
						Type of Plan: 

					
					
						Severance Pay Plan - Welfare Plan

				
	
					
						Name of Plan Sponsor:

					
					
						ImmunoGen, Inc.
830 Winter Street

					
						Waltham, MA 02451

					
						(781) 895-0600

					
						 

				
	
					
						Employer I.D. Number:

					
					
						04-2726691

				
	
					
						Plan Number:

					
					
						5 0 2

				
	
					
						Plan Administrator:

					
					
						ImmunoGen, Inc.

					
						c/o Chief Human Resources Officer
830 Winter Street

					
						Waltham, MA 02451

					
						 

				
	
					
						Plan Agent for Service 
of Legal Process:

					
					
						ImmunoGen, Inc.

					
						c/o General Counsel
830 Winter Street

					
						Waltham, MA 02451

					
						 

					
						Service of legal process also may be made on the Plan Administrator

					
						 

				
	
					
						Plan Year:

					
					
						January 1 through December 31

				

		
			 
		

		
			Amended effective as of September 23, 2016.
		

			
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						IMMUNOGEN INC.

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						By:

					
					
						   /s/ Mark J. Enyedy

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Title:

					
					
						   President and Chief Executive Officer

				
	
					
						 

					
					
						 

					
					
						 

				
	
					
						 

					
					
						Date:

					
					
						   September 23, 2016

				

		
			 
		

		 

		

			11

		

		

			ImmunoGen, Inc. Severance Pay Plan
 for Vice Presidents and Higher
Effective as of September 23, 2016

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00262-of-00352.parquet"}]]